2018 Behcet'S Disease Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Behcet'S Disease Market
Behcet’s disease or Behcet’s syndrome is a chronic and systemic inflammatory and auto-immune disorder that involves aphthous stomatitis, skin manifestations, eye inflammation and genital ulcers. The disease of unknown aetiology is more prevalent in Asian and Middle East countries compared to the prevalence in Americas. The rare condition is characterized by a relapsing remitting course, which affects multiple organs. Biologic therapy is considered as the most beneficial for disease control.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Behcet'S Disease pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Behcet'S Disease pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Behcet'S Disease pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Behcet'S Disease pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Behcet'S Disease pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Behcet'S Disease pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 BEHCET'S DISEASE PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Behcet'S Disease Pipeline Snapshot
2.3 Behcet'S Disease Pipeline by Phase
2.4 Behcet'S Disease Pipeline by Company
2.5 Behcet'S Disease Pipeline by Mechanism of Action
3 BEHCET'S DISEASE- COMPANY WISE PIPELINE ANALYSIS
AbbVie Inc
Celgene Corporation
Genor BioPharma Co
Novartis AG
R-Pharm JSC
4 BEHCET'S DISEASE R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN BEHCET'S DISEASE PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 BEHCET'S DISEASE PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Behcet'S Disease Pipeline Snapshot
2.3 Behcet'S Disease Pipeline by Phase
2.4 Behcet'S Disease Pipeline by Company
2.5 Behcet'S Disease Pipeline by Mechanism of Action
3 BEHCET'S DISEASE- COMPANY WISE PIPELINE ANALYSIS
AbbVie Inc
Celgene Corporation
Genor BioPharma Co
Novartis AG
R-Pharm JSC
4 BEHCET'S DISEASE R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN BEHCET'S DISEASE PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Behcet'S Disease Pipeline by Phase, H2- 2018
Figure 2: Behcet'S Disease Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Behcet'S Disease Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Behcet'S Disease Pipeline by Phase, H2- 2018
Figure 2: Behcet'S Disease Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Behcet'S Disease Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Behcet'S Disease Pipeline by Phase, H2- 2018
Behcet'S Disease Pipeline by Companies, H2- 2018
Behcet'S Disease Pipeline by Mechanism of Action, H2- 2018
Table 1: AbbVie Inc Behcet'S Disease Pipeline Drugs, H2- 2018
Table 2: Celgene Corporation Behcet'S Disease Pipeline Drugs, H2- 2018
Table 3: Genor BioPharma Co Behcet'S Disease Pipeline Drugs, H2- 2018
Table 4: Novartis AG Behcet'S Disease Pipeline Drugs, H2- 2018
Table 5: R-Pharm JSC Behcet'S Disease Pipeline Drugs, H2- 2018
Behcet'S Disease Pipeline by Phase, H2- 2018
Behcet'S Disease Pipeline by Companies, H2- 2018
Behcet'S Disease Pipeline by Mechanism of Action, H2- 2018
Table 1: AbbVie Inc Behcet'S Disease Pipeline Drugs, H2- 2018
Table 2: Celgene Corporation Behcet'S Disease Pipeline Drugs, H2- 2018
Table 3: Genor BioPharma Co Behcet'S Disease Pipeline Drugs, H2- 2018
Table 4: Novartis AG Behcet'S Disease Pipeline Drugs, H2- 2018
Table 5: R-Pharm JSC Behcet'S Disease Pipeline Drugs, H2- 2018
